AU2024228473A1 — Pharmaceutical composition comprising cytisine
Assigned to Adamed Pharma SA · Expires 2025-08-14 · 1y expired
What this patent protects
The present invention relates to a stabilized composition with significantly improved shelf-life stability. More particularly, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at…
USPTO Abstract
The present invention relates to a stabilized composition with significantly improved shelf-life stability. More particularly, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound. The present invention relates also to a use of at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound for the stabilization of a liquid aqueous pharmaceutical composition comprising cytisine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.